{"id":217311,"date":"2025-07-07T14:09:10","date_gmt":"2025-07-07T19:09:10","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/diabetes-drug-cuts-migraines-in-half-by-targeting-brain-pressure"},"modified":"2025-07-07T14:09:10","modified_gmt":"2025-07-07T19:09:10","slug":"diabetes-drug-cuts-migraines-in-half-by-targeting-brain-pressure","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/diabetes-drug-cuts-migraines-in-half-by-targeting-brain-pressure","title":{"rendered":"Diabetes drug cuts migraines in half by targeting brain pressure"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/diabetes-drug-cuts-migraines-in-half-by-targeting-brain-pressure.jpg\"><\/a><\/p>\n<p>A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drugs ability to lower brain fluid pressure is the key, potentially opening a completely new way to treat migraines. The effects were fast, sustained, and came with only mild side effects.<\/p>\n<p>A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.<\/p>\n<p>Researchers at the Headache Center of the University of Naples \u201cFederico II\u201d gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine (defined as \u226515 headache days per month). Patients reported an average of 11 fewer headache days per month, while disability scores on the Migraine Disability Assessment Test dropped by 35 points, indicating a clinically meaningful improvement in work, study, and social functioning.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drugs ability to lower brain fluid pressure is [\u2026]<\/p>\n","protected":false},"author":707,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1490,47],"tags":[],"class_list":["post-217311","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-government","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/707"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=217311"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217311\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=217311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=217311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=217311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}